Seres Therapeutics (MCRB) Total Non-Current Liabilities: 2017-2025
Historic Total Non-Current Liabilities for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to $97.8 million.
- Seres Therapeutics' Total Non-Current Liabilities fell 36.12% to $97.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.8 million, marking a year-over-year decrease of 36.12%. This contributed to the annual value of $124.2 million for FY2024, which is 69.09% down from last year.
- Per Seres Therapeutics' latest filing, its Total Non-Current Liabilities stood at $97.8 million for Q3 2025, which was down 10.22% from $108.9 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Total Non-Current Liabilities ranged from a high of $407.1 million in Q2 2024 and a low of $97.8 million during Q3 2025.
- For the 3-year period, Seres Therapeutics' Total Non-Current Liabilities averaged around $262.1 million, with its median value being $316.6 million (2023).
- Per our database at Business Quant, Seres Therapeutics' Total Non-Current Liabilities surged by 58.86% in 2022 and then plummeted by 73.25% in 2025.
- Seres Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $211.9 million in 2021, then soared by 58.86% to $336.6 million in 2022, then increased by 19.39% to $401.8 million in 2023, then plummeted by 69.09% to $124.2 million in 2024, then plummeted by 36.12% to $97.8 million in 2025.
- Its Total Non-Current Liabilities stands at $97.8 million for Q3 2025, versus $108.9 million for Q2 2025 and $111.8 million for Q1 2025.